P 16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin

International Journal of Gynecological Pathology

Volumn 31, Issue 1, 2012, Pages 57-65

  Saad, Reda S ^a   Mashhour, Miral ^a   Noftech Mozes, Sharon ^a   Ismiil, Nadia ^a   Dubé, Valérie ^a   Ghorab, Zeina ^a   Faragalla, Hala ^a   Khalifa, Mahmoud A ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Endometrioid carcinoma; P16; Undifferentiated carcinoma

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 7; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P16; VIMENTIN; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CLINICAL ARTICLE; CYTOPLASM; ENDOCERVICAL ADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA; ADENOCARCINOMA; CARCINOMA; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM TUMOR; METABOLISM; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA; CARCINOMA, ENDOMETRIOID; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84856686339     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318223118a     Document Type: Article

References (38)

1. Yemelyanova A, Vang R, Seidman JD, et al. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas. Utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol 2009;33:914-24.
2. Luran JR, Bidus MA, Elkas JC. Uterine cancer, cervical and vaginal cancer. In: Berek RS, ed. Novak's Gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2007: 1343-402.
3. Han CP, Lee MY, Kok LF, et al. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Int J Gynecol Pathol 2009;28: 489-96.
4. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004;28: 160-8.
5. Andersson S, Rylander E, Larson B, et al. Types of human papillomavirus revealed in cervical adenocarcinoma after DNA sequencing. Oncol Rep 2003;10:175-9.
6. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E and p16INK4a are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-91. (Pubitemid 32594981)
7. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003;22:231-5. (Pubitemid 36750403)
8. Missaoui N, Hmissa S, Frappart L, et al. p16INK4a overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch 2006;448:597-603. (Pubitemid 44490557)
9. Park TW, Zivanovic O, Theuerkauf I, et al. The diagnostic utility of human papillomavirus-testing in combination with immunohistochemistry in advanced gynecologic pelvic tumors: a new diagnostic approach. Int J Oncol 2004;24: 829-36.
10. Paquette RL, Brestovac B, Thompson J, et al. The value of HPV DNA typing in the distinction between adenocarcinoma of endocervical and endometrial origin. Pathology 2003;35: 397-401. (Pubitemid 37310980)
11. Staeber A, Sherman ME, Zaino RJ, et al. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol 2005;26:998-1006. (Pubitemid 34810560)
12. Mylonas I, Jeschke U, Shabani N, et al. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res 2005;25: 1679-86. (Pubitemid 40896785)
13. Chambers JT, Carcangiu ML, Voynick IM, et al. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol 1990;94:255-60. (Pubitemid 20275338)
14. Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endocervical and endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007;106:325-33. (Pubitemid 47087930)
15. Walhstrom T, Lindgren J, Korhonen M, et al. Distinction between endocervical and endometrial adenocarcinoma with immunoperoxidase staining of carcinoembryonic antigen in routine histologic tissue specimens. Lancet 1979;2:1159-60. (Pubitemid 10208361)
16. McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002;21:11-5. (Pubitemid 34008347)
17. Kamoi S, AlJuboury MI, Akin MR, et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol 2002;21:217-23. (Pubitemid 34680337)
18. Ronnett BM, Yemelyanova AV, Vang R, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol 2008;32:1835-53.
19. Altrabulsi B, Malpica A, deavers MT, et al. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 2005;29: 1316-21. (Pubitemid 41368767)
20. Silva EG, Deavers MT, Bodurka DC, Malpica A. Association of low grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 2006;25:52-8. (Pubitemid 44638336)
21. Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology 2007;39: 134-8.
22. Wells M, Ostor AG, Crum CP, et al. Tumors of the Uterine Cervix. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics: Tumors of the Breast and Female Genital Organs: World health Organization Classification of Tumors, Chapter 5. Lyon: IARC Press; 2003:260-83.
23. Mittal K, Soslow R, McCluggage WG. Application of immunohistochemistry to gynecologic pathology. Arch Pathol Lab Med 2008;132:402-23. (Pubitemid 351337535)
24. Koo CL, Kok LF, Lee MY, et al. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med 2009;7:25.
25. Kok LF, Lee MY, Tyan YS, et al. Comparing the scoring mechanisms of p16INK4a immunohistochemistry based on independent nucleic stains and independent cytoplasmic stains in distinguishing between endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obst 2010;281:293-300.
26. Milde-Langosch K, Bamberger AM, Goemann C, et al. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 2001;127:537-44. (Pubitemid 32757487)
27. Nakashima R, Fujita M, Enomoto T, et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 1999;80:458-67. (Pubitemid 29213201)
28. Shiozawa T, Nikaido T, Shimizu M, et al. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 1997;80: 2250-6. (Pubitemid 28007395)
29. Tsuda H, Yamamoto K, Inoue T, et al. The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid- type endometrial carcinoma. Br J Cancer 2000;82: 675-82. (Pubitemid 30085207)
30. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000;6:153-9. (Pubitemid 30064988)
31. Ignatov A, Bischoff J, Schwarzenau C, et al. p16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol 2008;111:365-71.
32. Yemelyanova A, Ji H, Shih IM, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas. Immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009;33: 1504-14.
33. Liao CL, Lee MY, Tyan YS, et al. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. J Transl Med 2009;7:37.
34. Han CP, Lee MY, Kok LF, et al. A reappraisal of threemarker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study. Arch Gynecol Obst 2010;281:845-50.
35. Liao CL, Hsu JD, Lee MY, et al. Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough? Virch Arch 2010. [Epub ahead].
36. Dallenbach-Hellweg G, Lang-Averous G, Hahn U. The value of immunohistochemistry in the differential diagnosis of endometrial carcinomas. APMIS Suppl 1991;23:91-9.
37. Dabbs DJ, Sturtz K, Zaino RJ. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol 1996;27:172-7. (Pubitemid 26049471)
38. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 2002;21:4-10. (Pubitemid 34008346)